Amgen Inc (AMGN) 160.25 $AMGN
Medical Device Companies Were Election Day Winners
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 11:00AM CST
Source: Library of Congress The shift in power in Washington may have big implications for medical device companies if legislation is rekindled to ditch the 2.3% medical device tax. That tax, enacted as part of Obamacare to help fund the cost of...
BIIB: 320.75 (-2.72), MDT: 68.10 (-0.64), AMGN: 160.25 (-0.10), SYK: 87.47 (-1.08)
Final Glance: Biotechnology companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Midday Glance: Biotechnology companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Early Glance: Biotechnology companies
AP - Fri Nov 07, 9:53AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 65.75 (-3.22), JNJ: 108.20 (-0.81), PCYC: 133.49 (-3.63), SHPG: 198.58 (-1.37), MRK: 59.34 (+0.08), AMGN: 160.25 (-0.10)
Amgen To Present At The Credit Suisse Annual Healthcare Conference
PR Newswire - Thu Nov 06, 3:30PM CST
Amgen (NASDAQ: AMGN) will participate at the Credit Suisse Annual Healthcare Conference on Tuesday, Nov. 11, 2014, at The Arizona Biltmore in Phoenix, beginning at 8:30 a.m. MT. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
AMGN: 160.25 (-0.10)
Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014
PR Newswire - Thu Nov 06, 3:01PM CST
Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company's oncology and hematology portfolios have been accepted for presentation at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH) being held Dec. 6 - 9, 2014, in San Francisco.
AMGN: 160.25 (-0.10)
The Zacks Analyst Blog Highlights:AbbVie, Regeneron, Aegerion, Geron and Amgen
PR Newswire - Thu Nov 06, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Regeneron (Nasdaq:REGN-Free Report), Aegerion (Nasdaq:AEGR-Free Report), Geron (Nasdaq:GERN-Free Report) and Amgen (Nasdaq:AMGN-Free Report).
AMGN: 160.25 (-0.10)
Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 7:36AM CST
AEGR data by YCharts What: Shares of Aegerion Pharmaceuticals , a biopharmaceutical company focused on developing drugs to treat rare diseases, collapsed in October and lost 40% of their value, based on data from S&P Capital IQ , after...
AMGN: 160.25 (-0.10), AEGR: 21.58 (-0.40)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 15.50 (-0.34), PFE: 29.92 (-0.12), AMGN: 160.25 (-0.10), AXN: 0.28 (-0.01), SRNE: 4.65 (+0.05), NKTR: 13.35 (-0.21), EGLT: 6.79 (-0.05), AZN: 72.88 (+0.03), VBAY: ()
Bone Metastasis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 31 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/t39trm/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Eli Lilly and Company - Takeda Pharmaceutical Company Limited - Sigma-Tau S.p.A. - Bayer AG - Medivir AB - Osteologix Holdings Plc. - Transgene SA - Merrion Pharmaceuticals Plc - Digna Biotech, S.L. - Debiopharm International S.A. - Amura Holdings Ltd. - Alethia Biotherapeutics Inc. - Deciphera Pharmaceuticals, LLC - Terpenoid Therapeutics, Inc. - R-Pharm - TWi Pharmaceuticals, Inc. - DexTech Medical AB - AlphaMab Co., Ltd Drug Profiles - denosumab - zoledronic acid - MLN-1202 - radium Ra 223 dichloride - Osteodex - MIV-711 - RPH-203 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Vicrostatin - ADM-01 - LY-2109761 - LY-364937 - Drugs to Inhibit EGFR for Bone Metastasis - (alendronate sodium paclitaxel PEG) - alendronate sodium HPMA paclitaxel - DCC-3014 - Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - TPH-9 - NBS-101 - Recombinant Protein to Inhibit Serine Protease for Bone Metastasis For more information visit http://www.researchandmarkets.com/research/t3...metastasis
AMGN: 160.25 (-0.10), LLY: 66.60 (-0.36)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 95.84 (+2.93), AMGN: 160.25 (-0.10), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
GlobeNewswire - Wed Nov 05, 3:38PM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced financial results for the third quarter ended September 30, 2014. These results are included in TetraLogic's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission.
AMGN: 160.25 (-0.10), TLOG: 3.95 (+0.12)
Uptrend Call Working As Amgen Stock Rises 14.0% (AMGN)
Comtex SmarTrend(R) - Wed Nov 05, 10:00AM CST
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on October 21st, 2014 at $141.25. In approximately 2 weeks, Amgen has returned 14.00% as of today's recent price of $161.02.
AMGN: 160.25 (-0.10)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 115.93 (-1.36), GERN: 2.33 (-0.07), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), AEGR: 21.58 (-0.40), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
Cloud Pharmaceuticals Announces World-Class Board of Directors
PR Newswire - Wed Nov 05, 7:00AM CST
Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today that it ratified its board of directors at its annual meeting on September 16, 2014. Members of the board include Cloud Pharmaceuticals Chairman and CEO, Ed Addison, CSO Shahar Keinan, PhD, and CIO Lawrence Husick. Other members of the board include:
AMGN: 160.25 (-0.10), LLY: 66.60 (-0.36)
5 Things Celgene Corporation's Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 6:51AM CST
Source: U.S. Department of Agriculture via Flickr . Following another successful quarterly report, investors and shareholders of Celgene have to be wondering if anything can stop this stock from heading higher . For the quarter, Celgene...
OMED: 20.19 (-0.02), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), CELG: 106.45 (-0.69)
Medical Device Companies Were Election Day Winners
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 08, 11:00AM CST
Source: Library of Congress The shift in power in Washington may have big implications for medical device companies if legislation is rekindled to ditch the 2.3% medical device tax. That tax, enacted as part of Obamacare to help fund the cost of...
BIIB: 320.75 (-2.72), MDT: 68.10 (-0.64), AMGN: 160.25 (-0.10), SYK: 87.47 (-1.08)
Final Glance: Biotechnology companies
AP - Fri Nov 07, 5:08PM CST
NEW YORK (AP) — Shares of some top biotechnology companies were down at the close of trading:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Midday Glance: Biotechnology companies
AP - Fri Nov 07, 12:18PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Early Glance: Biotechnology companies
AP - Fri Nov 07, 9:53AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 106.45 (-0.49), AMGN: 160.25 (-0.10), CELG: 106.45 (-0.69)
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 65.75 (-3.22), JNJ: 108.20 (-0.81), PCYC: 133.49 (-3.63), SHPG: 198.58 (-1.37), MRK: 59.34 (+0.08), AMGN: 160.25 (-0.10)
Amgen To Present At The Credit Suisse Annual Healthcare Conference
PR Newswire - Thu Nov 06, 3:30PM CST
Amgen (NASDAQ: AMGN) will participate at the Credit Suisse Annual Healthcare Conference on Tuesday, Nov. 11, 2014, at The Arizona Biltmore in Phoenix, beginning at 8:30 a.m. MT. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for 90 days following the event.
AMGN: 160.25 (-0.10)
Amgen Highlights New Data In The Treatment Of Blood Cancers At ASH 2014
PR Newswire - Thu Nov 06, 3:01PM CST
Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that more than 50 abstracts from the Company's oncology and hematology portfolios have been accepted for presentation at the 56th Annual Meeting and Exposition of the American Society of Hematology (ASH) being held Dec. 6 - 9, 2014, in San Francisco.
AMGN: 160.25 (-0.10)
The Zacks Analyst Blog Highlights:AbbVie, Regeneron, Aegerion, Geron and Amgen
PR Newswire - Thu Nov 06, 8:30AM CST
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Regeneron (Nasdaq:REGN-Free Report), Aegerion (Nasdaq:AEGR-Free Report), Geron (Nasdaq:GERN-Free Report) and Amgen (Nasdaq:AMGN-Free Report).
AMGN: 160.25 (-0.10)
Why Aegerion Pharmaceuticals, Inc. Stock Collapsed in October
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 06, 7:36AM CST
AEGR data by YCharts What: Shares of Aegerion Pharmaceuticals , a biopharmaceutical company focused on developing drugs to treat rare diseases, collapsed in October and lost 40% of their value, based on data from S&P Capital IQ , after...
AMGN: 160.25 (-0.10), AEGR: 21.58 (-0.40)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 15.50 (-0.34), PFE: 29.92 (-0.12), AMGN: 160.25 (-0.10), AXN: 0.28 (-0.01), SRNE: 4.65 (+0.05), NKTR: 13.35 (-0.21), EGLT: 6.79 (-0.05), AZN: 72.88 (+0.03), VBAY: ()
Bone Metastasis Therapeutics Pipeline Review, H2 2014 - 19 Companies & 31 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/t39trm/bone_metastasis) has announced the addition of the "Bone Metastasis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Metastasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Metastasis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - Eli Lilly and Company - Takeda Pharmaceutical Company Limited - Sigma-Tau S.p.A. - Bayer AG - Medivir AB - Osteologix Holdings Plc. - Transgene SA - Merrion Pharmaceuticals Plc - Digna Biotech, S.L. - Debiopharm International S.A. - Amura Holdings Ltd. - Alethia Biotherapeutics Inc. - Deciphera Pharmaceuticals, LLC - Terpenoid Therapeutics, Inc. - R-Pharm - TWi Pharmaceuticals, Inc. - DexTech Medical AB - AlphaMab Co., Ltd Drug Profiles - denosumab - zoledronic acid - MLN-1202 - radium Ra 223 dichloride - Osteodex - MIV-711 - RPH-203 - Debio-0719 - P-17 - disitertide - MIV-710 - SST-0001 - TG-3003 - AB-25E9 - AM-3701 - DCC-2909 - AC-301 - Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer - Vicrostatin - ADM-01 - LY-2109761 - LY-364937 - Drugs to Inhibit EGFR for Bone Metastasis - (alendronate sodium paclitaxel PEG) - alendronate sodium HPMA paclitaxel - DCC-3014 - Small Molecules to Inhibit GGDPS for Cancer and Bone Metastasis - TPH-9 - NBS-101 - Recombinant Protein to Inhibit Serine Protease for Bone Metastasis For more information visit http://www.researchandmarkets.com/research/t3...metastasis
AMGN: 160.25 (-0.10), LLY: 66.60 (-0.36)
Alnylam Pharmaceuticals, Inc. Has This Ratio Right
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 7:33PM CST
With no drugs on the market, Alnylam Pharmaceuticals ' third-quarter earnings were all about the pipeline progress it's made and plans going forward. During the conference call, there were 16 slides based on its pipeline and one devoted to...
ALNY: 95.84 (+2.93), AMGN: 160.25 (-0.10), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update
GlobeNewswire - Wed Nov 05, 3:38PM CST
TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced financial results for the third quarter ended September 30, 2014. These results are included in TetraLogic's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission.
AMGN: 160.25 (-0.10), TLOG: 3.95 (+0.12)
Uptrend Call Working As Amgen Stock Rises 14.0% (AMGN)
Comtex SmarTrend(R) - Wed Nov 05, 10:00AM CST
SmarTrend identified an Uptrend for Amgen (NASDAQ:AMGN) on October 21st, 2014 at $141.25. In approximately 2 weeks, Amgen has returned 14.00% as of today's recent price of $161.02.
AMGN: 160.25 (-0.10)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 115.93 (-1.36), GERN: 2.33 (-0.07), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), AEGR: 21.58 (-0.40), SNY: 45.69 (-0.17), REGN: 377.84 (+0.90)
Cloud Pharmaceuticals Announces World-Class Board of Directors
PR Newswire - Wed Nov 05, 7:00AM CST
Cloud Pharmaceuticals, Inc., a therapeutics company focused on cloud-based drug design and development, announced today that it ratified its board of directors at its annual meeting on September 16, 2014. Members of the board include Cloud Pharmaceuticals Chairman and CEO, Ed Addison, CSO Shahar Keinan, PhD, and CIO Lawrence Husick. Other members of the board include:
AMGN: 160.25 (-0.10), LLY: 66.60 (-0.36)
5 Things Celgene Corporation's Management Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 05, 6:51AM CST
Source: U.S. Department of Agriculture via Flickr . Following another successful quarterly report, investors and shareholders of Celgene have to be wondering if anything can stop this stock from heading higher . For the quarter, Celgene...
OMED: 20.19 (-0.02), AMGN: 160.25 (-0.10), ABBV: 61.50 (-1.21), CELG: 106.45 (-0.69)
